Popular Bisphosphonates News and Current Events

Popular Bisphosphonates News and Current Events, Bisphosphonates News Articles.
Sort By: Most Relevant | Most Recent
Page 1 of 6 | 208 Results
Many postmenopausal women do not receive treatment for osteoporosis
The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society. The Society introduced the guideline during a news conference on Monday at ENDO 2019, its annual meeting in New Orleans, La. (2019-03-25)

Mayo Clinic: New recommendations for use of bisphosphonates in treatment of multiple myeloma
Mayo Clinic's multiple myeloma (MM) research team has jointly issued a consensus statement regarding the use of bisphosphonates to prevent or treat bone disease in MM. Their recommendations address several controversial issues, including the type of bisphosphonate to be used and the duration of such therapy, and are available in the August issue of Mayo Clinic Proceedings. (2006-08-10)

Osteoporosis drug may benefit heart health
The osteoporosis drug alendronate was linked with a reduced risk of cardiovascular death, heart attack, and stroke in a Journal of Bone and Mineral Research study of patients with hip fractures. (2018-05-11)

Fifteen percent of osteoporosis patients who take 'drug holidays' suffer bone fractures
A Loyola Medicine study has found that 15.4 percent of patients who take so-called 'drug holidays' from osteoporosis drugs called bisphosphonates experienced bone fractures. During a six-year follow-up period, the yearly incidence of fractures ranged from 3.7 percent to 9.9 percent, with the most fractures occurring during the fourth and fifth years. (2018-05-04)

The delicate balance of treating growing but brittle bones
Turning off a bone receptor protein could potentially treat osteoporosis in children without affecting bone growth. (2019-02-01)

Task force provides guidance on use of osteoporosis drugs
A new report by a task force of the American Society for Bone and Mineral Research provides guidance on the use of bisphosphonates, which are the most commonly used medications for osteoporosis. (2016-01-19)

Investigating what keeps metastatic breast cancer in check
New evidence suggests that inflammation may help prevent growth of tumor cells that have spread, with important implications for clinical trials. (2018-08-27)

Women who discontinue bisphosphonates for two years or more have higher hip fracture risk
Women who took a drug holiday (temporary or permanent discontinuation of a medicine) from using bisphosphonates for more than two years have a significantly higher risk of a hip fracture compared to others who continued their treatment, according to new research findings presented this week at the 2017 ACR/ARHP Annual Meeting in San Diego. (2017-11-04)

New strategy against osteoporosis
An international research team has found a new approach that may be able to reduce bone loss in osteoporosis and maintain bone health. (2020-08-05)

Novartis submits NDA for Zometa® (zoledronic acid for injection)
Novartis Pharmaceuticals Corporation today announced that it has submitted a new drug application (NDA) to the U.S. Food and Drug Administration for Zometa (zoledronic acid for injection) for the treatment of tumor-induced hypercalcemia (TIH). A potentially life-threatening disorder, TIH is characterized by elevated serum calcium levels in patients with cancer. Tumor-induced hypercalcemia is one of the most common metabolic complications associated with cancer. (1999-12-21)

Patients 65 years of age or older with hip or spine fracture should be treated for osteoporosis
A coalition of the world's top bone health experts, physicians, specialists, and patient advocacy groups today released their clinical recommendations to tackle the public health crisis in the treatment of osteoporosis and the debilitating and often deadly hip and spine fractures caused by the disease. (2018-09-29)

Study finds one-third of women taking bisphosphonates remain at risk for fracture
A recent study of oral bisphosphonates, the most commonly prescribed osteoporosis treatment, found that approximately a third of women prescribed these drugs continue to be at elevated risk for bone fracture, an outcome that may have several origins. The retrospective cohort study was conducted under the auspices of a Regenstrief Institute-Merck collaboration. (2016-06-06)

US older women three times as likely to be treated for osteoporosis as men
Older women in the US are three times as likely to be treated for osteoporosis as men of the same age, reveals research published online in the Journal of Investigative Medicine. (2019-02-14)

Sex-specific effects of DHEA on bone mineral density and body composition
Women 55 and older have an increased risk of bone and muscle loss but therapy with the hormone Dehydroepiandrosterone (DHEA) may help prevent bone loss and increase muscle mass in older women, according to a new study led by Catherine M. Jankowski, PhD, FACSM, an exercise physiologist and associate professor at the University of Colorado College of Nursing at the Anschutz Medical Campus. (2018-12-04)

Osteoporosis treatment may also protect against pneumonia
A recent study published in the Journal of Bone and Mineral Research found that nitrogen-containing bisphosphonates (N-BPs) such as alendronate, which are widely used to treat postmenopausal osteoporosis, are linked with lower risks of pneumonia and of dying from pneumonia. (2020-06-03)

Experts question automatic osteoporosis drug holidays
A new editorial published in the journal Osteoporosis International urges physicians to individualize treatment decisions based on their patients' fracture risk, rather than automatically interrupting or stopping bisphosphonate therapy after five or three years. (2016-01-04)

Failure to discontinue medications can contribute to inappropriate prescribing
The continuation of drugs that are not intended to be taken indefinitely is a substantial and common problem that could contribute to over-medication, particularly in the elderly. (2018-11-12)

Bisphosphonates increasingly prescribed to the women most likely to benefit
In recent years, women who start taking bisphosphonates (BPs) to treat osteoporosis and prevent fracture have trended from younger to older and from having osteopenia to having osteoporosis, researchers report. The results of the study will be presented on Saturday at ENDO 2019, the Endocrine Society's annual meeting in New Orleans, La. (2019-03-23)

Bone drug may be beneficial for knee osteoarthritis
Bisphosphonates (a class of drugs that prevent the loss of bone density and used to treat osteoporosis and similar diseases) appear to be safe and beneficial for osteoarthritis patients. (2020-08-05)

Study supports bisphosphonate use prior to denosumab to prevent loss of bone mineral density in post-menopausal women
The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) finds the risk of bone mineral density (BMD) loss after denosumab discontinuation is associated with younger age, high bone turnover markers, and not receiving the bisphosphonate, zoledronate, prior to initiation of denosumab. (2019-06-13)

Some bisphosphonates users unfamiliar with drug's possible side effects on oral health
People undergoing bisphosphonate therapy to prevent or treat osteoporosis (a thinning of the bones) may be unfamiliar with the drug and possible adverse side effects on oral health, according to a study in the May issue of the Journal of the American Dental Association. (2010-05-26)

Study provides insights on optimal treatment of Paget's disease of bone
In a study of patients with Paget's disease of bone--a common skeletal disorder that can lead to bone deformity, fractures, osteoarthritis, and bone pain -- long-term intensive bisphosphonate therapy conferred no clinical benefit over giving bisphosphonates only when patients felt bone pain. (2017-02-08)

SWOG shares trio of studies at San Antonio breast cancer symposium
SWOG Cancer Research Network members will share the results of three studies at the San Antonio Breast Cancer Symposium, an international gathering of breast cancer physicians and researchers that starts today, with an estimated 7,500 attendees expected from more than 90 countries. (2018-12-04)

Surgery associated with reduced fractures in patients with hyperparathyroidism
Surgery to remove the parathyroid was associated with reduced fracture risk in patients with primary hyperparathyroidism, whereas bisphosphonate treatment was associated with increased bone mineral density but not fewer fractures. The observational study was published in Annals of Internal Medicine. (2016-04-04)

Bone markers as screening strategy for patient adherence to osteoporosis medications
This IOF and ECTS Working Group position paper proposes measuring specific bone turnover markers (BTMs) in patients who have initiated use of oral bisphosphonates for postmenopausal osteoporosis as a practical way to identify low adherence. BTMs can reflect the early effect of the drug on bone tissue. If low response is detected shortly after treatment begins, this may indicate low adherence or point to underlying causes of impaired response to medication. (2017-01-30)

Treating bone loss in breast cancer survivors
Osteoporosis is a growing concern among breast cancer survivors and their doctors, because certain cancer drugs can cause bone loss. A new study has found that bone loss can be halted with a comprehensive regimen that includes both osteoporosis drugs and treatments that target secondary causes of bone loss. (2009-09-15)

Study: Denosumab effective in treating osteoporosis in transfusion dependent thalassemia
For patients with osteoporosis caused by transfusion-dependent thalassemia (TDT), a twice-yearly injection appears to improve spinal bone mineral density, according to a new study. (2018-10-31)

Risks of esophagus cancer studied: Statins may protect against esophageal cancer
Statin use is associated with protection from esophagus cancer according to a new meta-analysis of existing clinical studies exploring the cancer prevention effects of statins presented by a Mayo Clinic researcher, Dr. Siddharth Singh, at the American College of Gastroenterology 77th Annual Scientific Meeting in Las Vegas, Nev. (2012-10-22)

New way to target and kill antibiotic-resistant bacteria found
Putting bacteria on birth control could stop the spread of drug-resistant microbes, and researchers at the University of North Carolina at Chapel Hill have found a way to do just that. (2007-07-09)

Quantity vs. quality: Long-term use of bone-building osteoporosis drugs
Bisphosphonate treatments, proven to enhance bone density and reduce fracture incidence in post-menopausal women, may adversely affect bone quality and increase risk of atypical fractures of the femur when used for four or more years, according to preliminary research presented today at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons. (2010-03-10)

IOF review of impact of drug holidays on bone health
The impact of interruption of anti-osteoporosis treatment in patients on therapy with bisphosphonates or denosumab is reviewed in a new IOF Working Group paper. The aim of the study was to assess what evidence exists to inform decision making on drug holidays and to identify any indicators that might help clinicians decide whether to continue or discontinue therapy in individual patients. (2019-07-08)

Once-yearly treatment significantly reduces bone fractures in women with postmenopausal osteoporosis
Phase III clinical trial shows effectiveness of once-yearly treatment for postmenopausal osteoporosis. (2007-05-02)

Study examines the effects of osteoporosis drugs in children with genetic bone disorders
Previous case reports in patients with osteogenesis imperfecta (OI) have suggested that treatment with bisphosphonates, which are commonly prescribed for osteoporosis, may be associated with atypical femur fractures. A new retrospective study of 119 children with OI indicates that such fractures are related to the severity of OI rather than to bisphosphonate use, however. (2017-01-09)

Confusion about long-term treatment of osteoporosis clarified
Osteoporosis is a common disorder among postmenopausal women which results in an increased risk of fractures. While several therapies improve bone strength and reduce the risk of spine and hip fracture, there is no cure for osteoporosis, and long-term treatment is needed. An upcoming presentation at The North American Menopause Society (NAMS) Annual Meeting in Philadelphia Oct. 11-14 is scheduled to present new evidence about the long-term effectiveness and safety of treatment with bisphosphonates and denosumab. (2017-10-11)

Study sheds light on atypical periprosthetic femoral fractures
Following surgery, some patients experience a broken bone around the implants of a total hip replacement--called a periprosthetic femoral fracture. (2018-10-03)

Study highlights underlying mechanisms of fractures associated with osteoporosis drug
There is no disputing that the use of bisphosphonates -- with brand names such as Fosamax, Boniva and Reclast -- is proven to combat bone loss and fragility fractures in millions of osteoporosis patients for whom a fracture could be debilitating, even life-threatening. (2017-07-31)

USC research shows remedy for painful jaw disease
USC researchers and collaborators report a breakthrough to prevent osteonecrosis of the jaw, a side effect suffered by some people undergoing treatment for cancer or osteoporosis. (2019-04-11)

Specific long-term therapy may not prevent fractures in older women
Bisphosphonates are sometimes used to treat osteoporosis. Studies have shown that the risk for bone fractures lessens when women with low bone mineral density take these medications for between one and four years. However, little is known about whether taking bisphosphonates for longer has the same effect. A team of researchers examined whether older women taking bisphosphonates for 10-13 years had fewer bone fractures than older women with similar fracture risks who took these medicines only briefly. (2017-06-02)

New drug agent knocks out multiple enzymes in cancer pathway
A team of 24 researchers from the US, Europe, Taiwan and Japan and led by University of Illinois scientists has engineered a new anti-cancer agent that is about 200 times more active in killing tumor cells than similar drugs used in recent clinical trials. The study appears this week in the Journal of the American Chemical Society. (2009-03-25)

SWOG spotlights high-impact research at ASCO
At ASCO 2019, SWOG investigators will report on 16 group-led trials, one jointly-led study, and another 12 involving partners. Presentation topics illustrate SWOG's wide-ranging portfolio, with talks and posters on treatment or prevention of bladder, breast, colorectal, lung, pancreatic, prostate, and rare cancers, as well as melanoma and multiple myeloma. SWOG investigators will make a particularly strong showing in symptom control, survivorship, and quality of care trials. (2019-05-22)

Page 1 of 6 | 208 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.